0001104659-24-006381.txt : 20240125 0001104659-24-006381.hdr.sgml : 20240125 20240125060016 ACCESSION NUMBER: 0001104659-24-006381 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240122 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: VAN NOSTRAND ROBERT L CENTRAL INDEX KEY: 0001225198 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33958 FILM NUMBER: 24558448 MAIL ADDRESS: STREET 1: C/O ACHILLION PHARMACEUTICALS, INC. STREET 2: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc. CENTRAL INDEX KEY: 0001390478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 6462005278 MAIL ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Galena Biopharma, Inc. DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: GALENA BIOPHARMA, INC. DATE OF NAME CHANGE: 20110922 4 1 tm243935-6_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-01-22 0 0001390478 SELLAS Life Sciences Group, Inc. SLS 0001225198 VAN NOSTRAND ROBERT L C/O SELLAS LIFE SCIENCES GROUP, INC., 7 TIMES SQUARE, SUITE 2503 NEW YORK NY 10036 1 0 0 0 0 Common Stock 2024-01-22 4 A 0 6000 0.00 A 10400 D Stock Option (Right to Buy) 0.5195 2024-01-22 4 A 0 10000 0 A 2034-01-22 Common Stock 10000 10000 D The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. /s/ Robert L. Van Nostrand 2024-01-24